Advertisement

Document › Details
BioNTech SE. (7/9/19). "Press Release: BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline". Mainz.
— One of the largest private EU biotech funding events expands global shareholder base —
BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced the completion of a USD 325 million Series B financing round, making it one of the largest single private funding rounds for a biotechnology company in European history. The fund raising was upsized and was led by Fidelity Management & Research Company with participation from both new and existing investors, including Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office. Two-thirds of the funding came from new investors. The proceeds of the financing will support the continued advancement of BioNTech’s therapeutics pipeline and manufacturing infrastructure.
“BioNTech has executed on a highly disruptive business strategy that aims to change the treatment paradigm for cancer patients,” said Helmut Jeggle, Chairman of BioNTech. “We value the continued participation of our existing investors and welcome new investors to this powerful global syndicate representing North America, Asia and Europe.”
Prof. Ugur Sahin, CEO and Co-Founder of BioNTech added: “This financing round is a significant milestone that recognizes our scientific and initial clinical track record to date. With our ongoing focus on bringing together transformative technologies, it is exciting to have the support from high-technology investors who see the accelerating convergence of biology with bioinformatics, robotics and artificial intelligence as an opportunity to develop more precise, efficacious and cost-effective individualized immunotherapies.”
The funding follows the Series A financing of USD 270 million announced in January 2018, led by Redmile Group. The previous financings have enabled BioNTech to advance a pipeline of seven product candidates in eight ongoing clinical trials, to establish a second GMP manufacturing license for production of its individualized neoantigen specific immunotherapies and to expand its antibody platform, most recently, through the acquisition of a Phase I/IIa program against pancreatic cancer from MabVax Therapeutics Inc. In conjunction with the MabVax Therapeutics acquisition of assets, the company has also recently established its US research and development facility in San Diego, California.
About BioNTech
BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech’s product development approach has been validated by seven collaborations with, in chronological order, Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 150 peer-reviewed scientific publications. BioNTech’s shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. For more information, please see: www.biontech.de.
For more information, please contact:
BioNTech SE
Michael Boehler, MD, Head of Global External Communications
Tel: +49 (0)6131 9084 1640
Email: Michael.Boehler@biontech.de
For all media inquiries:
Trophic Communications
Gretchen Schweitzer / Stephanie May, PhD
Tel: +49 (0)89 23 88 77 30 or +49 171 185 56 82
Email: May@trophic.eu
Record changed: 2019-07-09 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for BioNTech (Group)
- [1] Evonik Industries AG. (2/11/21). "Press Release: Evonik Strengthens Strategic Partnership with BioNTech on COVID-19 Vaccine". Essen....
- [2] BioNTech SE. (12/29/20). "Press Release: Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of Comirnaty". New York, NY & Mainz....
- [3] BioNTech SE. (12/23/20). "Press Release: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine". New York, NY & Mainz....
- [4] BioNTech SE. (12/21/20). "Press Release: Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine". New York, NY & Mainz....
- [5] BioNTech SE. (12/21/20). "Press Release: Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine". New York, NY & Mainz....
- [6] BioNTech SE. (12/19/20). "Press Release: Pfizer and BioNTech Receive Conditional Marketing Authorization by Swissmedic for COVID-19 Vaccine". Zürich & Mainz....
- [7] BioNTech SE. (12/16/20). "Press Release: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine". Mainz & Shanghai....
- [8] BioNTech SE. (12/12/20). "Press Release: U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older". New York, NY & Mainz....
- [9] BioNTech SE. (12/11/20). "Press Release: Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19". New York, NY & Mainz....
- [10] BioNTech SE. (11/25/20). "Press Release: BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies". Mainz & London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top